Channel Therapeutics Corpora
13F holders, Q3 2024 (September 30)5holders
3new positions
3sold out
$0.71avg. 13F price*
At the end of Q3 2024, 5 institutions reported holding Channel Therapeutics Corpora in their 13F filings, unchanged from Q2 2024. 3 opened new positions and 3 sold out. The largest holders were Avantax Planning Partners, Inc. ($34K), Two Sigma Securities, LLC ($19K) and Wealth Enhancement Advisory Services, LLC ($7K).
- Company
- Channel Therapeutics Corpora
- Filed as
- CHROMOCELL THERAPEUTICS CORP (Q3 2024)
- CUSIP
- 171126105
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $59K |
| Exits | 3 | $290K |
All 13F filers, Q2 2024 → Q3 2024: 83,921 shares bought and 219,930 shares sold, net −136,009 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Avantax Planning Partners, Inc. | 0.00% | New | 47,205 | $34K |
| Two Sigma Securities, LLC | 0.00% | New | 26,061 | $19K |
| Wealth Enhancement Advisory Services, LLC | 0.00% | New | 10,400 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +4216.7% | 259 | $184 |
| Bank of America Corp. | 0.00% | Add +22.2% | 11 | $8 |
"% of holder's portfolio" is CHANNEL THERAPEUTICS CORPORA's weight in each manager's 13F, not the share of Channel Therapeutics Corpora the manager owns.